CHITOSE-BIO-EVOLUTION
14.9.2023 15:01:36 CEST | Business Wire | Press release
CHITOSE BIO EVOLUTION PTE. LTD., the leader of the global bioeconomy and the headquarters of the CHITOSE Group (hereinafter "CHITOSE"), has successfully concluded a total of 21M USD new share issuances through a third-party allotment with Shiseido Company, Limited, NGK INSULATORS, LTD., Mitsui Mining & Smelting Co. Ltd. (*1), Mitsubishi Kakoki Kaisha.Ltd., Amano Enzyme Inc., Mers Line Pte. Ltd. (*2), Ikeda tohka Industries Co., Ltd. and SHINSHO CORPORATION. The funds raised will be allocated towards the expansion of the microalgae production facility and R&D of product applications in order to accelerate MATSURI, the project to build a microalgae-based industry to replace the petroleum industry. Through these commitments, CHITOSE will contribute to the realization of zero carbon emissions and work together with others toward a prosperous future that will last beyond a thousand years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230914666208/en/
Microalgae Production Scale Roadmap (Graphic: Business Wire)
*1 Investment by Mitsui Kinzoku-SBI Material Innovation Fund with Mitsui Mining & Smelting Co. Ltd. as a Limited Partnership and SBI Investment as a General Partnership.
*2 Investment by Sun Sail Navigation Pte. Ltd., which belongs to the Mers Line Pte Ltd. group.
Rationale for the Capital Increase & Use of Proceeds
CHITOSE envisions a future in which humankind can live prosperously for the next thousand years and aims to build an unprecedented microalgae-derived industry. Working in collaboration with progressive companies and organizations spanning various sectors and industries, CHITOSE is simultaneously expanding the scale of production and developing multifaceted applications in order to promote the use of microalgae products in fuels, foods, chemical products, cosmetics, and feedstuffs that support people's lives.
In terms of scale-up of microalgae production facilities, following completion of a 0.1 hectare facility in August 2018, CHITOSE successfully inaugurated a 5 hectare-facility named CHITOSE Carbon Capture Central (C4) in April 2023. CHITOSE plans to expand it further to a scale of 2,000 hectares by 2030 and 10 million hectares by 2050. In the current fiscal year, CHITOSE has just launched the 2,000 hectare-project, of which the initial 100 hectare-facility development along with the R&D of various applications have been selected as a commissioned project by the Green Innovation Fund / Promotion of Carbon Recycling Using CO2 from Biomanufacturing Technology as a Direct Raw Material (*3) of NEDO (*4).
*3 About the Green Innovation Fund Project / Promotion of Carbon Recycling Using CO2 from Biomanufacturing Technology as a Direct Raw Material
https://green-innovation.nedo.go.jp/en/project/bio-manufacturing-technology/
*4 New Energy and Industrial Technology Development Organization
Future Procurement Plans
Growing expectations for stable procurement of resources and contribution to sustainable manufacturing enabled us to achieve our target of 20M USD for the current fiscal year during the first half of the year. Responding to strong market demand, CHITOSE intends to continue vigorous dialogue with investors in the second half of the year and beyond.
*Note: All figures are the exchange value of the USD calculated as of September 8, 2023.
Stakeholder’s Comments
Shiseido Company, Limited
"Under our mission of 'BEAUTY INNOVATIONS FOR A BETTER WORLD,' our company is committed to developing cosmetics that are not only good for the skin, but also promotes a healthy and beautiful natural environment. We are working with the CHITOSE Group to build a circular model, maximizing the potential of 'algae,' and integrating it into the earth's system, ensuring resources are not depleted. We will lead the creation of sustainable value, thereby revitalizing the global cosmetics market."
NGK INSULATORS, LTD.
"NGK, a member of MATSURI, is encouraged to develop algae business that contributes to carbon neutrality with our unique ceramic technologies. NGK and CHITOSE Group will extend our collaboration to realize social implementation of the bio industry."
Mitsui Mining & Smelting Co., Ltd.
"Mitsui Mining & Smelting Co., Ltd. is working to co-create a value chain for bio-manufacturing by applying our unique catalyst, separation and purification technologies in order to contribute to the realization of a sustainable society."
Mitsubishi Kakoki Kaisha, Ltd.
"Mitsubishi Kakoki Kaisha believes that algae can be a solution to the global food and energy problems, and this investment is in line with our long-term management vision. We will work closely with the MATSURI project and contribute to the development of the algae business with our technology."
Mers Line Pte. Ltd.
"With the utilization of microalgae, a carbon-free society is just around the corner. We sympathize with the philosophy of CHITOSE Group, 'To live in abundance beyond the next millennium using the ability of living things' and support their activities."
Ikeda tohka Industries Co.,Ltd.
"As a food ingredient manufacturer with over 100 years of history, we harness our cultivated food processing technology to convert algae biomass into a usable form for industries. Through this, we support the creation of a sustainable and carbon-neutral society."
SHINSHO CORPORATION
"Through this investment, we intend to collaborate with CHITOSE Group, in order to build a new resource-recycling business model through carbon recycling and new business development using microalgae."
###
About MATSURI
https://matsuri-partners.chitose-bio.com/en
The MATSURI project aims towards the establishment of an advanced microalgae-based industry. CHITOSE has considerable expertise in large-scale photosynthetic production technologies, and is leading the MATSURI project collaborating with Japanese progressive enterprises. As what MATSURI means in Japanese, CHITOSE keeps leading a festival to develop a sustainable society. If you are interested in MATSURI, please feel free to contact the MATSURI office. Click here to contact us.
Related Information
[Press Release] CHITOSE Group, Successfully Concludes Capital Increase of 7M USD Scale from Shiseido and Forms Strategic Partnership ― Accelerate a Microalgae-based Circular Manufacturing in a Cosmetic Industry —
[Press Release] CHITOSE Group Obtains Funding from Japanese Government(NEDO) for Green Innovation Fund of 400M USD Scale
[MATSURI partner site] Shiseido Company, Limited Joined MATSURI as a Corporate Partner (Japanese)
[MATSURI partner site] Amano Enzyme Inc. Joined MATSURI as an Industry Restructuring Partner (Japanese)
CHITOSE Group Overview
https://chitose-bio.com/
CHITOSE Group is a family of biotechnology companies leading the global bioeconomy. To live in abundance beyond the next millennium using the ability of living things, CHITOSE pursues the possibilities of biotechnology through technological and business development collaborating with its business partners all over the world.
About CHITOSE BIO EVOLUTION PTE. LTD. (head office that oversees entire Group)
Established in October, 2011
Head Office located in Singapore
CEO: Tomohiro FUJITA, Ph. D.
About CHITOSE Laboratory Corp. (responsible for the project)
Established in November, 2002
Head Office located in Kanagawa Prefecture, Japan
CEO: Tomohiro FUJITA, Ph. D.
COO: Rie KUGIMIYA
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230914666208/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
